GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat ...

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

RAPT Therapeutics shares surged after GSK agreed to acquire the biotech for $2.2 billion, adding a promising food allergy ...

GSK signed an agreement to acquire RAPT Therapeutics for around $2.2 billion. ・The deal centers on an experimental allergy ...

GSK said Tuesday that it made a deal to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash. The acquisition is expected to close in the first quarter of 2026 with an ...

The growing scourge of food allergies drove U.K. heavyweight pharmaceutical GSK to announce a $2.2 billion deal on Tuesday.

Dr. Geetika Sabharwal has been honored with a 2025 Global Recognition Award for her sustained contributions to allergy and ...

Drug-induced fever can complicate antibiotic treatment and lead to unnecessary testing when cultures are negative, and ...